No.

Publication Date

Citing Article

1

2026

Hai Zhang, Xinyi Liu, Yunhua Zhao, Hong Fang, Yujiao Wang, Lin Chen. Selinexor as a multi-pathway regulator of the XPO1-inflammation Axis: Mechanisms, evidence in inflammatory diseases, and translational challenges, International Immunopharmacology. 2026; 187: 117185117185.  https://doi.org/10.1016/j.intimp.2026.117185

2

2026

Andrea Adrados, Juan Pérez-Fernández, Roberto García-Vicente, Alba Garrote-de-Barros, Joaquín Martinez-Lopez, María Linares, María Hernández-Sánchez. Enhancing immunotherapy efficacy in multiple myeloma and chronic lymphocytic leukemia: from combinatorial therapeutic approaches to gut microbiota modulation, Frontiers in Immunology. 2026; 17: 1805129.  https://doi.org/10.3389/fimmu.2026.1805129

3

2026

Daniel T Harding, Lara V Graham, Laura G Bartlett, Nancy Gudgeon, Jack G Fisher, Christopher J Walker, Trinayan Kashyap, Charlotte E Brookes, Aidan Haslam, Graham McIlroy, Guy Pratt, Ben M Amram, Georgia Francis, Mark S Cragg, Salim I Khakoo, Sarah Dimeloe, Matthew D Blunt. Selinexor potentiates NK cell activation against multiple myeloma, Clinical and Experimental Immunology. 2026; 220: uxag059.  https://doi.org/10.1093/cei/uxag059

4

2025

Kezia Gitareja, Shalini S. Chelliah, Elaine Sanij, Shahneen Sandhu, Jian Kang, Amit Khot. Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy, Cancers. 2025; 17: 2534.  https://doi.org/10.3390/cancers17152534

5

2025

Maria Vittoria Di Marco, Alessandro Gasparetto, Roberto Chiarle, Claudia Voena. Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer, Cells. 2025; 14: 1991.  https://doi.org/10.3390/cells14241991

6

2026

Rashidul Islam, Anne Waldhaus, Isabella Federica Bollen, Lea Descher, Amir Shalan, Valentina Alejandra Araya Balde, Annalena Liesen, Andjela Kovacevic, Gina Esther Merges, Glen Kristiansen, Hubert Schorle. 2026;   https://doi.org/10.64898/2026.09.14.750914

7

2026

Zhengchao Yan, Sijuan Tang, Chunhua Tang, Minhui He, Yuan Lin, Minxia Li, Shuang Liang, Jianbin Yang, Fangting Luo, Liwu Zhang, Jianlin Chen. 2026;   https://doi.org/10.21203/rs.3.rs-10742446/v1

8

2026

Chuanxu Liu, Dahui Li, Yan Gao, Wenhao Zhang, Zhi Guo, Jun Zhao, Huiqiang Huang, Rong Tao. Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial, The Oncologist. 2026; 31: oyag266.  https://doi.org/10.1093/oncolo/oyag266

9

2026

Hardany PRIMARIZKY, Satoshi KAMBAYASHI, Kenji BABA, Kenji TANI, Masaru OKUDA. Combination effect of Exportin 1 inhibitor (KPT-335) with doxorubicin or vincristine in canine lymphoma cell lines, Journal of Veterinary Medical Science. 2026; 88: 25-0478119.  https://doi.org/10.1292/jvms.25-0478

10

2026

Zengli Kuang, Yu Chen, Cuiai Ren. Efficacy analysis and adverse event management of selinexor in the treatment of relapsed/refractory multiple myeloma, Frontiers in Medicine. 2026; 13: 1927209.  https://doi.org/10.3389/fmed.2026.1927209

11

2026

Seema Yadav, Anshul Shinde, Jyoti Rani, Ravindresh Chhabra. CRM1 as a potential biomarker and therapeutic target in cancer: a comprehensive review, The Nucleus. 2026;   https://doi.org/10.1007/s13237-026-00684-0